QT
MLTX icon

Quantbot Technologies’s MoonLake Immunotherapeutics MLTX Stock Holding History

Quantbot Technologies’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.84K Sell
99
-6,167
-98% -$102K ﹤0.01% 1610
2025
Q4 		$82.6K Buy
+6,266
New +$73.9K ﹤0.01% 1452
2025
Q3 		– Sell
-49
Closed -$2.31K – 1983
2025
Q2 		$2.31K Buy
+49
New +$2K ﹤0.01% 1572

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Quantbot Technologies's MLTX Position: Q1 2026 in Review

Quantbot Technologies reduced its MoonLake Immunotherapeutics (MLTX) stake by 98% in Q1 2026, selling an estimated $102K and leaving 99 shares worth $1.84K. The position accounts for ﹤0.01% of the portfolio, ranked #1610.

Quantbot Technologies first reported a position in MLTX in Q2 2025 and has held it in 3 quarters since. The position peaked at $82.6K in Q4 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Quantbot Technologies held 99 shares of MoonLake Immunotherapeutics worth $1.84K as of Q1 2026.
  • Quantbot Technologies sold 6,167 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $102K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Quantbot Technologies's portfolio in Q1 2026, its #1610 holding.
  • Quantbot Technologies first reported a position in MoonLake Immunotherapeutics in Q2 2025 and has held it in 3 quarters since.
  • Quantbot Technologies's MoonLake Immunotherapeutics position peaked at $82.6K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Quantbot Technologies's 13F filing for Q1 2026, filed 13 May 2026.